The discovery of orally available thrombin inhibitors: Studies towards the optimisation of CGH1668

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 24, 1998, Pages 3583-3588

  Ambler, John ^a   Baker, Emma ^a   Brown, Lyndon ^a   Butler, Paul ^a   Farr, Dave ^a   Dunnet, Karen ^a   Le Grand, Darren ^a   Janus, Diana ^a   Jones, Darryl ^a   Menear, Keith ^a   Mercer, Mark ^a   Smith, Garrick ^a   Talbot, Mark ^a   Tweed, Morris ^a  

^a Novartis Horsham Research Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CGH 1668; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HEMOSTASIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HUMANS; PARTIAL THROMBOPLASTIN TIME; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0032534848     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00640-4     Document Type: Article

References (13)

1. 1. Takada, Akikazu; Takada, Yumiko; Urano, Tetsumei. The physiological aspects of fibrinolysis. Thromb. Res. (1994), 76(1), 1-31.
2. 2. Kaiser Brigitte. Thrombin and factor Xa inhibitors. Drugs of the Future. (1998), 23(4), 423-436.
3. 3. Turpie, Alexander G. G.; Weitz, Jeffrey I.; Hirsh, Jack. Advances in antithrombotic therapy: novel agents. Thromb. Haemostasis (1995), 74(1), 565-571.
4. 4. Fenton, J. W., II; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagulation Fibrinolysis (1991), 2(1), 69-75.
5. 5. Ammar, H. O.; Ghorab, M.; El-Nahhas, S. A.; Makram, T. S. Improvement of the biological performance of oral anticoagulant drugs. Part I. Warfarin. Pharmazie (1997), 52(8), 627-631.
6. 6. Hirsh, J. Heparins. Fibrinolysis (1995), 9(Suppl. 1), 66-68.
7. 7. Fareed, Jawed; Walenga, Jeanine M.; Hoppensteadt, Debra; Ahsan, Ahmed; Murphy, Rosemary; Weber, Stephanie; Pifarre, Roque. Pharmacological profile of low molecular weight heparins: implications in prophylaxis and the treatment of thrombotic disorders. Low Mol. Weight Heparins Clin. Pract. (1992), 63-84. Editor(s): Doutremepuich, Christian. Publisher: Dekker, New York, N. Y.
8. 8. Kimball, S. D. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagulation Fibrinolysis (1995), 6(6), 511-519.
9. 9. Ripka, William C.; Vlasuk, George P. Antithrombotics/serine proteases. Annu. Rep. Med. Chem. (1997), 32, 71-89.
10. 10. Kikumoto, Ryoji; Tamao, Yoshikuni; Ohkubo, Kazuo; Tezuka, Tohru; Tonomura, Shinji; Okamoto, Shosuke; Hijikata, Akiko. Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Na-substituted L-arginine. J. Med. Chem. (1980), 23(12), 1293-1299.
11. 11. For convenience pharmacophores residing in the S9 pocket, also known as the distal or aryl pocket, of thrombin are referred to as P3.
12. 12. Studies relating to the discovery of CGH1668 in press. Bioorg. Med. Chem. Lett.
13. 13. Craig, Paul N. Interdependence between physical parameters and selection of substituent groups for correlation studies. J. Med. Chem. (1971), 14(8), 680-684.